Josep Tabernero, MD, PhDEnriched profile
Director, Vall d'Hebron Institute of Oncology (VHIO); Head, Medical Oncology Department, Vall d'Hebron University Hospital (HUVH) · Vall d'Hebron Institut de Recerca
Overview
Updated 14 Jul 2026
Josep Tabernero is Director, Vall d'Hebron Institute of Oncology (VHIO). The public record shows 2,704 publications with 129,261 citations (h-index 148), centered on Colorectal Cancer Treatments and Studies, Gastric Cancer Management and Outcomes, Lung Cancer Treatments and Mutations. It also documents an investigator role on 19 registered clinical trials.
- Most recent indexed publication: 2026 · Nature medicine
- Top research focus: Colorectal Cancer Treatments and Studies
- 19 registered trials on ClinicalTrials.gov
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 112 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 826.
Clinical & industrytrials, payments and federal funding
Not shown. No U.S. clinical registration on file.
Federally funded research awards.
Public positionssourced statements on record
- Chairman
Cancer Core Europe consortium (since 2023), pan-European alliance of comprehensive cancer centers advising on EU cancer research policy
2023verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vhio.net ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vhio.net ↗
This is a research profile, built on the published record. There's no U.S. clinical registration (NPI) on file, so facts that hang off one (clinical specialty, industry payments) aren't shown. We'd rather leave a gap than guess. Why? →
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 19 registered studies on ClinicalTrials.gov. The most recent:
- A Study Testing SOT109 for the First Time in Patients, to Assess How Safe SOT109 is, How Well it Works, and How the Body Handles it in Patients With Advanced Colorectal Cancer That Can Not be Removed by Surgery or is Metastatic
Sponsor: SOTIO Biotech a.s.
InvestigatorPhase 1/PHASE2Not, yet, recruitingNCT07693751 - Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers
Sponsor: Translational Research in Oncology
InvestigatorPhase 2WithdrawnNCT05582031 - Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma
Sponsor: SOTIO Biotech a.s.
InvestigatorPhase 1/PHASE2TerminatedNCT05525286
Industry payments
Not shown. This person has no U.S. clinical registration (NPI) on file, so we can't reliably tie industry payments reported to CMS to them. We'd rather leave a gap than guess. Why? →
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 14 Jul 2026
574 congress contributions (2004–2025) across AACR, ASCO, ASTRO, ESMO, SABCS per OpenAlex. The most recent:
- Abstract 4997: The ROSALIND Study: Identifying multi-omic signatures in long-term cancer survivors for therapeutic target discovery
AACR Annual Meeting
AACR2025Co-author - Abstract CT093: Cancer Core Europe - Basket of Baskets - first results from module 1: Atezolizumab in genomically selected populations
AACR Annual Meeting
AACR2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma.
Clinical cancer research
2026
Most-cited worksby citation count (OpenAlex)
- 01Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine6,671 citations2013
- 02The consensus molecular subtypes of colorectal cancer5,269 citations2015
- 03The landscape of somatic copy-number alteration across human cancers4,138 citations2010
- 04
- 05
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
Vall d'Hebron Institute of Oncology
Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vallhebron.com ↗
- PhD in Medicine and Surgery
Universitat Autònoma de Barcelona
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vallhebron.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vallhebron.com ↗
- Executive Master in Healthcare Organization Management
ESADE Business School
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vallhebron.com ↗ - Advanced Business Management Program
IESE Business School
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vallhebron.com ↗
Editorial & leadership rolesjournal and society appointments
- Director
Vall d'Hebron Institute of Oncology (VHIO)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vallhebron.com ↗ - Head
Medical Oncology Department, Vall d'Hebron University Hospital (HUVH)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vallhebron.com ↗ - Head
Molecular Cancer Therapy Research Unit / Phase I clinical trials unit, Vall d'Hebron Hospital
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vallhebron.com ↗
Awards & honorshonors on the public record
- 2025 Barcelona Gold Medal for Scientific Merit (Medalla d'Or al Mèrit Científic)
awarded by Barcelona City Council
2025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →barcelona.cat ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vhio.net ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vhio.net ↗
Secondary affiliationsappointments beyond the home institution
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →esmo.org ↗
- Full Professor of Medicine
Universitat de Vic – Universitat Central de Catalunya (UVic-UCC)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →esmo.org ↗ - Professor of Medicine (teaching unit)
Universitat Autònoma de Barcelona, at Vall d'Hebron Hospital
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vallhebron.com ↗
Media & interviewspress, podcasts and appearances
- "Making a Difference: A Conversation With Josep Tabernero, MD, PhD"
feature interview, Oncology Times, July 2024
2024provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →journals.lww.com ↗ - "Tabernero Finds New Paths in Gastrointestinal Treatment Landscape"
feature interview, OncLive
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - "Josep Tabernero: It's a privilege to have been honored as a new FASCO recipient"
interview feature, OncoDaily
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncodaily.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- LinkedIn
linkedin.com/in/josep-tabernero
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/Josep-Tabernero
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - ResearchGate
researchgate.net/profile/Josep-Tabernero-2
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by otherswhere others cite or feature them
- Instagram
instagram.com/vhiobarcelona/p/C3vVFV_M6vV
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →instagram.com ↗ - Other
vhio.net/biosketch-josep-tabernero
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vhio.net ↗ - X / Twitter
X/Twitter account @TaberneroJosep
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Eric Van Cutsem, MD, PhD
Universitair Ziekenhuis Leuven
- 1,845
- publications
- 177
- h-index
- 14
- trials
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
- 1,745
- publications
- 154
- h-index
- 22
- trials
Charles Fuchs, MD, MPH
Yale Cancer Center
- 1,721
- publications
- 172
- h-index
- 7
- trials
John Buse, MD
University of North Carolina School of Medicine
- 1,053
- publications
- 141
- h-index
- 5
- trials